These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21732797)

  • 1. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study.
    Bohannon N; Bergenstal R; Cuddihy R; Kruger D; List S; Massaro E; Molitch M; Raskin P; Remtema H; Strowig S; Whitehouse F; Brunelle RL; Dreon D; Tan M
    Diabetes Technol Ther; 2011 Oct; 13(10):1031-7. PubMed ID: 21732797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.
    Bergenstal RM; Peyrot M; Dreon DM; Aroda VR; Bailey TS; Brazg RL; Frias JP; Johnson ML; Klonoff DC; Kruger DF; Ramtoola S; Rosenstock J; Serusclat P; Weinstock RS; Naik RG; Shearer DM; Zraick V; Levy BL;
    Diabetes Technol Ther; 2019 May; 21(5):273-285. PubMed ID: 31025878
    [No Abstract]   [Full Text] [Related]  

  • 3. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
    Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
    Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for a new prefilled insulin pen compared with the original pen.
    Garg S; Bailey T; DeLuzio T; Pollom D
    Curr Med Res Opin; 2011 Dec; 27(12):2323-33. PubMed ID: 21988614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch.
    Peyrot M; Dreon D; Zraick V; Cross B; Tan MH
    Diabetes Ther; 2018 Feb; 9(1):297-307. PubMed ID: 29327220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles.
    Bergenstal RM; Johnson ML; Aroda VR; Brazg RL; Dreon DM; Frias JP; Kruger DF; Molitch ME; Mullen DM; Peyrot M; Richter S; Rosenstock J; Serusclat P; Vance C; Weinstock RS; Levy BL
    J Diabetes Sci Technol; 2022 Sep; 16(5):1167-1173. PubMed ID: 34008442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
    Ignaut DA; Schwartz SL; Sarwat S; Murphy HL
    Diabetes Educ; 2009; 35(5):789-98. PubMed ID: 19783767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.
    Danne T; Forst T; Deinhard J; Rose L; Moennig E; Haupt A
    J Diabetes Sci Technol; 2012 Nov; 6(6):1392-7. PubMed ID: 23294785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
    Chen JW; Lauritzen T; Bojesen A; Christiansen JS
    Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients.
    Lee IT; Liu HC; Liau YJ; Lee WJ; Huang CN; Sheu WH
    J Eval Clin Pract; 2009 Aug; 15(4):699-703. PubMed ID: 19674222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus.
    Peyrot M; Rubin RR; Chen X; Frias JP
    Diabetes Technol Ther; 2011 Apr; 13(4):471-6. PubMed ID: 21355725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.
    Wang T; Conrad KA; van Brunt K; Rees TM
    J Diabetes Sci Technol; 2016 Jul; 10(4):923-31. PubMed ID: 26920640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.